Schizophrenia 17

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia 17

MalaCards integrated aliases for Schizophrenia 17:

Name: Schizophrenia 17 54 71 29 69
Schizophrenia Susceptibility Locus Chromosome 2p16-Related 71
Schizophrenia, Susceptibility to, 17 13
Sczd17 71


External Ids:

OMIM 54 614332
MedGen 40 C3280524
MeSH 42 D012559

Summaries for Schizophrenia 17

UniProtKB/Swiss-Prot : 71 Schizophrenia 17: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

MalaCards based summary : Schizophrenia 17, is also known as schizophrenia susceptibility locus chromosome 2p16-related. An important gene associated with Schizophrenia 17 is NRXN1 (Neurexin 1). The drugs Aripiprazole and Olanzapine have been mentioned in the context of this disorder. Affiliated tissues include brain and thyroid.

OMIM : 54
Deletions at 2p16.3 involving exons of NRXN1 are associated with susceptibility to autism, schizophrenia (SCZD17), developmental delay, intellectual disability, and dysmorphic features. The phenotype is highly variable and shows incomplete penetrance (summary by Dabell et al., 2013). For a phenotypic description and a discussion of genetic heterogeneity of schizophrenia, see 181500. (614332)

Related Diseases for Schizophrenia 17

Symptoms & Phenotypes for Schizophrenia 17

Clinical features from OMIM:


Drugs & Therapeutics for Schizophrenia 17

Drugs for Schizophrenia 17 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
Allopurinol Approved Phase 4 315-30-0 2094
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
Ethanol Approved Phase 4 64-17-5 702
Haloperidol Approved Phase 4 52-86-8 3559
11 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
13 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
14 Quetiapine Fumarate Phase 4,Phase 3,Phase 2 111974-72-2
15 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Antiemetics Phase 4,Phase 3,Phase 1
17 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
23 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Antiparkinson Agents Phase 4,Phase 3,Phase 2
26 Anti-Infective Agents Phase 4,Phase 2
27 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Antidepressive Agents Phase 4,Phase 2
31 Antidepressive Agents, Second-Generation Phase 4,Phase 2
32 Cholinergic Agents Phase 4,Phase 2
33 Cholinergic Antagonists Phase 4,Phase 2,Phase 3
34 Muscarinic Antagonists Phase 4,Phase 2
35 Parasympatholytics Phase 4,Phase 2
36 Antimetabolites Phase 4
37 Antioxidants Phase 4
38 Antirheumatic Agents Phase 4,Phase 2,Phase 3
39 Protective Agents Phase 4,Phase 2
40 Anticonvulsants Phase 4,Phase 2
41 Antimanic Agents Phase 4
42 GABA Agents Phase 4
43 Anti-Infective Agents, Local Phase 4
44 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Phase 1
45 Paliperidone Palmitate Phase 4,Phase 3,Phase 1
46 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 1
47 decanoic acid Phase 4
48 Haloperidol decanoate Phase 4
49 Brexpiprazole Approved Phase 3,Phase 1 913611-97-9 11978813
Asenapine Approved Phase 2, Phase 3,Phase 1 85650-56-2, 65576-45-6 3001386

Interventional clinical trials:

(show top 50) (show all 87)

id Name Status NCT ID Phase Drugs
1 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
2 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
3 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4 Olanzapine
4 Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram Completed NCT00707863 Phase 4 Escitalopram
5 Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression Completed NCT00824044 Phase 4 Escitalopram
6 Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia Completed NCT00864825 Phase 4 Allopurinol
7 Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder Completed NCT00199966 Phase 4 Divalproex sodium extended release
8 Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
9 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia Recruiting NCT02435654 Phase 4 olanzapine
10 Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia Recruiting NCT03075657 Phase 4 Risperidone;Risperidone and Ramelteon;Haloperidol;Haloperidol and Ramelteon
11 Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers in First Episode Untreated Schizophrenia Recruiting NCT03304457 Phase 4 Olanzapine;Lurasidone
12 The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia Not yet recruiting NCT03080194 Phase 4 paliperidone palmitate;control group
13 Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia Terminated NCT00998608 Phase 4 risperidone
14 Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal Withdrawn NCT00781755 Phase 4 varenicline
15 A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia Completed NCT01942148 Phase 3 Aripiprazole
16 A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients Completed NCT00518323 Phase 3 Paliperidone ER;Placebo;Paliperidone ER;Paliperidone ER
17 A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia Completed NCT01942161 Phase 2, Phase 3 Aripiprazole Low (2 mg/day);Aripiprazole Mid (6 - 12 mg/day);Aripiprazole High (24 - 30 mg/day)
18 An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia Completed NCT01009047 Phase 3 Paliperidone extended release (ER);Aripiprazole
19 Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. Completed NCT00488319 Phase 3 Paliperidone ER
20 Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia Completed NCT00051298 Phase 3 Olanzapine;Placebo
21 Investigate Risperidone for the Treatment of Schizophrenia in Adolescents Completed NCT00088075 Phase 3 Risperidone
22 Brexpiprazole in Patients With Acute Schizophrenia Completed NCT01810380 Phase 3 Placebo;Brexpiprazole;Quetiapine extended release
23 Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder Completed NCT00113594 Phase 3 Olanzapine
24 Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation Completed NCT00065286 Phase 3
25 Mindfulness-based Illness Management Program for Schizophrenia Completed NCT01667601 Phase 2, Phase 3
26 Bioequivalence Fasting Study in Patients Completed NCT02072954 Phase 2, Phase 3 Asenapine Sublingual Tablets 10 mg;Asenapine Sublingual Tablets 10 mg
27 Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue Completed NCT01794429 Phase 3 Exenatide;Placebo
28 Open-label Ziprasidone Study for Psychosis Treatment in Adolescents Completed NCT00421954 Phase 3 Ziprasidone
29 Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD) Completed NCT00671853 Phase 3 Quetiapine XR;Placebo for quetiapine XR
30 Safety and Efficacy of Cariprazine in Patients With Schizophrenia Completed NCT01104766 Phase 3 Cariprazine;Cariprazine;Aripiprazole;Placebo
31 Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia. Completed NCT00790192 Phase 3 Lurasidone;Lurasidone;Quetiapine XR;Placebo
32 Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia Completed NCT00789698 Phase 3 Lurasidone HC1;Quetiapine XR
33 Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia Recruiting NCT03238326 Phase 3 Brexpiprazole
34 Trial to Evaluate the Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia Recruiting NCT03198078 Phase 3 Brexpiprazole (OPC-34712);Aripiprazole;Placebo
35 Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia Recruiting NCT03121586 Phase 3 Pimavanserin
36 Aspirin in Young Psychotic Patients Recruiting NCT02685748 Phase 2, Phase 3 Aspirin;Placebo;Pantoprazole
37 Berberine as Adjuvant Treatment for Schizophrenia Patients Not yet recruiting NCT02983188 Phase 2, Phase 3 Berberine;Placebos;Antipsychotic Agents
38 Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia Terminated NCT00257192 Phase 3 placebo;Ziprasidone oral capsules
39 Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia Terminated NCT00265382 Phase 3 Ziprasidone oral capsules
40 Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents Terminated NCT01184443 Phase 3 Olanzapine
41 Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia Terminated NCT01363349 Phase 2, Phase 3 CYP-1020;Risperidone
42 Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT01099059 Phase 2 Amantadine;ritalin
43 Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder Unknown status NCT01099072 Phase 2 Methylphenidate+placebo;methylphenidate+carnitine
44 A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms Completed NCT01052103 Phase 2 LY2140023;Placebo;Standard of Care
45 The Purpose of the Study is to Determine Whether Cariprazine is a Safe and Tolerated Long-term Treatment in Patients With Chronic Stable Schizophrenia Completed NCT00839852 Phase 2 Cariprazine
46 D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia Completed NCT00960219 Phase 2 D-amino acid oxidase inhibition (DAAOI-1);placebo
47 N-methylglycine (Sarcosine) Treatment for Depression Completed NCT00977353 Phase 2 citalopram;sarcosine
48 Clinical Estradiol Trial in Women With Schizophrenia Completed NCT00206570 Phase 2 Estradiol
49 A Definitive Estrogen Patch Study (ADEPT) Completed NCT00357006 Phase 2 Estradiol;Estradiol
50 Effect of Estrogen & Stress for Postmenopausal Women Completed NCT00220454 Phase 2 Climara;Hydrocortone

Search NIH Clinical Center for Schizophrenia 17

Genetic Tests for Schizophrenia 17

Genetic tests related to Schizophrenia 17:

id Genetic test Affiliating Genes
1 Schizophrenia 17 29

Anatomical Context for Schizophrenia 17

MalaCards organs/tissues related to Schizophrenia 17:

Brain, Thyroid

Publications for Schizophrenia 17

Variations for Schizophrenia 17

ClinVar genetic disease variations for Schizophrenia 17:

id Gene Variation Type Significance SNP ID Assembly Location
1 NRXN1 NRXN1, 4-BP INS, 4205ACGG insertion risk factor

Expression for Schizophrenia 17

Search GEO for disease gene expression data for Schizophrenia 17.

Pathways for Schizophrenia 17

GO Terms for Schizophrenia 17

Cellular components related to Schizophrenia 17 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 8.62 CKB NRXN1

Sources for Schizophrenia 17

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....